Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT01028716 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01028716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01028716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
May 19, 2010
Completion date
October 7, 2021
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute biphenotypic leukemia, acute erythroid leukemia in remission, acute leukemia in remission, acute lymphoblastic leukemia in remission, acute myeloid leukaemia with prior myelodysplastic syndrome, acute myeloid leukemia in remission, acute myeloid leukemia with flt3/itd mutation, acute myeloid leukemia with inv(3)(q21q26.2); rpn1-evi1, acute myeloid leukemia with multilineage dysplasia, acute myeloid leukemia with t(6;9), acute undifferentiated leukemia, adult acute lymphoblastic leukemia in complete remission, b acute lymphoblastic leukemia with t(1;19)(q23;p13.3); e2a-pbx1 (tcf3-pbx1), blasts under 5 percent of bone marrow nucleated cells, burkitt lymphoma, childhood acute lymphoblastic leukemia in complete remission, ds stage ii plasma cell myeloma, ds stage iii plasma cell myeloma, hematopoietic cell transplant recipient, myelodysplastic syndrome, ph+ all, recurrent anaplastic large cell lymphoma, recurrent follicular lymphoma, recurrent hodgkin lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent plasma cell myeloma, refractory plasma cell myeloma, secondary acute myeloid leukemia, t lymphoblastic lymphoma